Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer
Authors:
- Francesca RagusaFRFrancesca Ragusa
- Silvia Martina FerrariSFSilvia Martina Ferrari
- Giusy EliaGEGiusy Elia
- Sabrina Rosaria PaparoSPSabrina Rosaria Paparo
- Eugenia BalestriEBEugenia Balestri
- Chiara BotriniCBChiara Botrini
- Armando PatrizioAPArmando Patrizio
- Valeria MazziVMValeria Mazzi
- Giovanni GuglielmiGGGiovanni Guglielmi
- Rudy FoddisRFRudy Foddis
- Claudio SpinelliCSClaudio Spinelli
- Salvatore UlisseSalvatore Ulisse
Open Access
- 20 May 2022
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (10) , 5731
Abstract
Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immunotherapy individually have many limitations. Regarding the first one, although it greatly reduces the size of the cancer, clinical responses are generally transient and often lead to cancer relapse after initial treatment. For the second one, although it induces longer-lasting responses in cancer patients than targeted therapy, its response rate is lower. The individual limitations of these two different types of therapies can be overcome by combining them. Here, we discuss MAPK pathway inhibitors, i.e., BRAF and MEK inhibitors, combined with checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4. Several mutations make tumors resistant to treatments. Therefore, more studies are needed to investigate the patient’s individual tumor mutation burden in order to overcome the problem of resistance to therapy and to develop new combination therapies.Keywords
This publication has 165 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trialThe Lancet Oncology, 2012
- The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Phase II Study of Daily Sunitinib in FDG-PET–Positive, Iodine-Refractory Differentiated Thyroid Cancer and Metastatic Medullary Carcinoma of the Thyroid with Functional Imaging CorrelationClinical Cancer Research, 2010
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium studyThe Lancet Oncology, 2010
- Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2010
- International patterns and trends in thyroid cancer incidence, 1973–2002Cancer Causes & Control, 2008